Giá lên

AVEO missed earnings - kidney cancer treatment too thinly traded

Cập nhật
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Ghi chú
ảnh chụp nhanh
Currently at 618fibretracement
Ghi chú
Full 241% retracement and bounce to 161%. Sign of bouncing cat?
Beyond Technical AnalysisclinicalentrypointFibonaccifullretracementkidneyLOWNEWoncologypharmaceuticalspharmastocksSupply and Demand

Thông báo miễn trừ trách nhiệm